Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) - Caffo, O; Facchini, G; Gasparro, D (J Clin Oncol, 2014)
et al.